1. Gelbard MK. Dystrophic penile calcification in Peyronie's disease. J Urol. 1988 Apr;139(4):738-40.

2. Kadioglu A, Küçükdurmaz F, Sanli O. Current status of the surgical management of Peyronie's disease. Nat Rev Urol. 2011 Feb;8(2):95-106.

3 Martinez D, Ercole CE, Hakky TS, Kramer A, Carrion R. Peyronie's Disease: Still a Surgical Disease. Adv Urol. 2012;2012:2062-84.

4. Smith BH. Subclinical Peyronie's disease. Am J Clin Pathol. 1969 Oct;52(4):385- 9.

5. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, Natali A, Vaggi L, Catuogno C, Giustini M, Taggi F; SIMONA Study Group. Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001 Nov;40(5):525-30.

6. Hatzimouratidis K, Eardley I, Giuliano F, et al.; European Association of Urology. EAU guidelines on penile curvature. Eur Urol 2012;62:543-52.

7.1. Levine LA, Estrada CR, Storm DW, Matkov TG. Peyronie disease in younger men: characteristics and treatment results. J Androl 2003;24:27-32.

7.2 Yachia D, Beyar M, Aridogan IA, Dascalu S. The incidence of congenital penile cur-vature. J Urol 1993;150:1478-9.

8. Schwarzer U, Sommer F, Klotz T, Braun M, Reifenrath B, Engelmann U. The prevalence of Peyronie's disease: results of a large survey. BU Int 2001;88:727-30.

9. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States.

10. Stunt M, Perlaky A, des Vignes F, Kyriakides T, Glass D. The prevalence of Revronie's disease in the United States: a population-based study. PLos One 2016;11: 0150157.

11 Shiraishi K, Shimabukuro T, Matsuyama H. The prevalence of Peyronie's discase in Japan: a study in men undergoing maintenance hemodialysis and routine heals checks. J Sex Med 2012;9:2716-23.

12. Hatzimouratidis K, Eardley I, Giuliano F, et al.; European Association of Urology. EAU guidelines on penile curvature. Eur Urol 2012;62:543-52.

13. Arafa M, Eid H, El-Badry A, Ezz-Eldine K, Shamloul R. The prevalence of Peyronie's disease in diabetic patients with erectile dysfunction. Int ] Impot Res 2007;19:213-17.

14. Usta MF, B Relationship k ities in men wi

15. La Pera G, Pescatori ES, Calabrese M, Boffini A, Colombo F, Andriani E, et al Peyronie's disease: prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol 2001;40:525-30.

16. Pavone C, D'Amato F, Dispensa N, Torretta F, Magno C. Smoking, diabetes, blood hypertension: possible etiologic role for Peyronie's disease? Analysis in 279 patients with a control group in Sicily. Arch Ital Urol Androl 2015;87:20-4.

17. Kadioglu A, Sanli O, Akman T, Canguven O, Aydin M, Akbulut F, et al. Factos affecting the degree of penile deformity in Peyronie disease: an analysis of 1001.

18. Pavone C, D'Amato F, Dispensa N, Torretta F, Magno C. Smoking, diabetes, blood hypertension: possible etiologic role for Peyronie's disease? Analysis in 279 patients with a control group in Sicily. Arch Ital Urol Androl 2015;87:20-4. 

19. Hambleton G,Macleod AF,Binless JT. IsPeyronie's diseaseiatrogenic? J R Coll Gen Pract. 1983 Jan;33(246):60. 

20. Bjekic MD. Risk factors for peyronie’s disease: a case-control study. BJU int2006 97:570-4. 

21. Nugteren HM, Nijman JM, de Jong IJ, van Driel MF. The association between Peyronie's and Dupuytren's disease. Int J Impot Res. 2011 Jul- 

22. Gudmundsson KG, Jónsson T, Arngrímsson R. Association of Morbus Ledderhose With Dupuytren's Contracture. Foot Ankle Int. 2013 Jun;34(6):841-5 

23. Abernethy J. The consequences of gonorrhea. Lecture on anatomy, surgery and pathology: including observations on the nature and treatment of local diseases. 1st ed. James Bulcock, London: Delivered at St Bartholomew's and Christ's Hospitals; 

24. Hindocha S, John S, Stanley JK, Watson SJ, Bayat A. The heritability of Dupuytren's disease: familial aggregation and its clinical significance. J Hand Surg Am 2006;31:204-10. 

25. Nyberg Jr. IM, Bias WB, Hochberg MC, Walsh PC. Identification of an inherited form of Peyronie's disease with autosomal dominant inheritance and association with Dupuytren's contracture and histocompatibility B7 cross-reacting antigens. J Urol 1982;128:48-51. 

26 Nugteren HM, Nijman JM, de Jong I, van Driel ME. The association between Peyronie's and Dupuytren's disease. Int J Impot Res 2011;23:142-5. 

27. Bjekic MD, Vlajinac HD, Sipetic SB, et al. Risk factors for Peyronie’s disease: a case-control study. BJU Int 2006, 97: 570-4. 

28. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. A population-based study of Peyronie's disease: prevalence and treatment patterns in the United States. 

29. Frank H. Netter, Atlante di anatomia umana, terza edizione, Elsevier Masson, 2007.; Anatomia del Gray; Zanichelli, 4ª edizione italiana;Trattato di anatomia umana, Edi. Ermes, 4ª Edizione 

30. Faysal A Yafi, Laith alzweri, Ian R McCaslin, Russel P Libby, Premsant, Sangkum, Suresh C Sikka, Wayne J G Hellstrom Grower or shower? Predictors of change in penile length from the flaccid to erect state. Int J Impot Res. 2018 Nov; 30(6):287-291 

31. Bjekic MD, Vlajinac HD, Sipetic SB, et al. Risk factors for Peyronie’s disease: a case-control study. BJU Int 2006, 97: 570-4. 

32. Herati AS, Pastuszak AW. The genetic basis of Peyronie disease: a review. Sex Med Rev 2016;4:85-94. 

33. Ralph DJ, Schwartz G, Moore W, et al. The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997, 157: 291-4. 

34. Zorba OU, Sirma S, Ozgon G, Salabas E, Ozbek U, Kadioglu A. Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea. Adv Clin Exp Med. 2012 Sep-Oct;21(5):607-14. 

35. Somers KD, Winters BA, Dawson DM, Leffell MS, Wright Jr. GL, Devine Jr. C). et al. Chromosome abnormalities in Peyronie's disease. J Urol 1987;137:672-5. 

36. Imai S, Kaksonen M, Raulo E, Kinnunen I, Fages C, Meng X, et al. Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM). J Cell Biol 1998;143:1113-28. 

37. Yoshimura H, Nakahama K, Safronova O, Tanaka N, Muneta T, Morita I. Transforming growth factor-beta stimulates IL-1beta-induced monocyte chemoat-tractant protein-1 expression in human synovial cells via the ERK/AP-1 pathway. Inflamm Res 2006;55:543-9. 

38. Pang Disor 

39. Qin tic he Am 

40. Herati Rev 26 

41. Willscher MK, Cwazka WF, Novicki DE. The association of histocompatibility antigens of the B7 cross-reacting group with Peyronie's disease. J Urol 1979;122:34-5. 

42. Mulhall Int J Imp 

43. El-Sakka disease. A 

44. . Hambleton G,Macleod AF,Binless JT. IsPeyronie's diseaseiatrogenic? J R Coll Gen Pract. 1983 Jan;33(246):60. 

45. AI-Thakafi S, Al genetics, pathop 280-9. 

46 Gonzalez-Cadavid NF, Rajfer J. Mechanisms of disease: new insights into the cellular and molecular pathology of Peyronie's disease. Nat Clin Pract Urol 2005;2: 291-7. 

47 Mateus M, Ilg MM, Stebbeds WJ, Christopher N, Muneer A, Ralph DJ, et al Understanding the role of adenosine receptors in the myofibroblast transformation in Peyronie's disease. I Sex Med 2018;15:947-57. 

48 Milenkovic U, Ilg MM, Cellek S, Albersen M. Pathophysiology and future thera. peutic perspectives for resolving fibrosis in Peyronie's disease. Sex Med Rev 2019;. 

49. Milenkovic U, Ilg MM, Zuccato C, Ramazani Y, De Ridder D, Albersen in. Simvastatin and the Rho-kinase inhibitor Y-27632 prevent myofibroblast transformation in Pevronie's disease-derived fibroblasts via inhibition of YAP/TAZ nuclear translocation. BJU Int 2019;123:703-15. 

50. Cantini LP, Fertini MG, Vernet D, Magee TR, Qian A, Gelfand RA, et al. Profibrotic role of myostatin in Peyronie's disease. J Sex Med 2008;5:1607-22. 

51. Mulhall JP, Creech SD, Boorjian SA. Subjective and objective analysis of the prevalence of Peyronie’s disease in a population of men presenting for prostate cancer screening. J Urol 2004, 171: 2350-3. 

52. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie’s disease. J Urol 2006, 175: 2115-8. 

53. Karin S, Coyne MPH, Brooke M, et al. The test-retest reliability of the Peyronie’s disease questionnaire. J Sex Med 2015, 12: 543-8. 

54. Ohebshalom M, Mulhall J, Guhring P, et al. Measurement of penile curvature in Peyronie’s disease patients: comparison of three methods. J Sex Med 2007, 4: 199-203. 

55. Kelami, A.: Classification of congenital and acquired penile de- viation. Urol Int, 38: 229, 1983 

56.. Mulhall JP, Schiff J, Guhring P. An analysis of the natural history of Peyronie's dis ease. J Urol 2006;175:2115 - 18. 

57.. Kadioglu A, Tefekli A, Erol B, Oktar I, Tunc M, Tellaloglu S. A retrospective review of 307 men with Peyronie's disease. J Urol 2002;168:1075-9. 

58.. Gelbard MK, Dorey F, James K. The natural history of Peyronie's disease. J Urol1990;144:1376-9. 80. Alenghat FJ, Ingber DE. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Science's STKE: Signal Transduct Know Environ 2002:2002 

59. (AUA) Linea guida. J Urol 2015;194:745-53 

60. Bodner H, HOWARD AH, KAPLAN JH. Peyronle’s disease: cortisone- hyaluronidase-hydrocortisone therapy. J Urol 1954; 72: 400-403 

61. Winter CC, Khanna R. Peyronie’s disease: results with dermo-jet injection of dexamethasone. J Urol 1975; 114: 898-900 

62. Cipollone G, Nicolai M, Mastroprimiano G, Iantorno R, Longeri D, Tenaglia R. Betamethasone versus placebo in Peyronie’s disease. Arch Ital Urol Androl 1998; 70: 165-168 

63. Roth M, Eickelberg O, Kohler E, Erne P, Block LH. Ca2+ channel blockers modulate metabolism of collagens within the extracellular matrix. Proc Natl Acad Sci USA 1996; 93: 5478-5482 

64. Shirazi M, Haghpanah AR, Badiee M, Afrasiabi MA, Haghpanah S. Effect of intralesional verapamil for treatment of Peyronie’s disease: a randomized single- blind, placebo-controlled study. Int Urol Nephrol 2009; 41: 467-471 

65.. Fitch WP, Easterling WJ, Talbert RL, Bordovsky MJ, Mosier M. Topical verapamil HCl, topical trifluoperazine, and topical magnesium sulfate for the treatment of Peyronie’s disease--a placebo-controlled pilot study. J Sex Med 2007; 4: 477-484 

66. soh J. Kavauchi A, Kanenitent Yo. aya Y. Ochiat A, Naitoh Y, ct al. Nicardipine Jo saline injection as treatment for Peyronie's disease: a prospective, randomized, single-blind trial. J. Sex Med 2010,7:3743-9. 

67. mehrsai AR, comparison of transdermal electromotive administration of verapamil and dexamethasone versus intra-lesional injection for peyronie’s disease. Andrology 2013:1:129-32 

68 Montori E Saloromotive man ordinGg, Barbier 4, Colombo I, Brats M, et al. Monsdermal electromotive multi-drug administration for Peyronie's disease: pretta. nary results. J Androl n.d.;21:85-90. 

69. Toscano jr. ILl, Rezende diVide to ma Pres L. Paulilo D: Crlina S. A prospective., randomized, single - blind study comparing intraplaque injection of thiocolchicine and verapamil in Peyronie's Disease: a pilot study. Int Braz ] Urol 2016;42:1005 - 9. 

70. Masterson TA, Rezk A, Ramasamy R. Characteristics predictive of response to colla-genase clostridium histolyticum for Peyronie's disease: a review of the literature World J Urol 2019 

71. Yaf FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost I W, et al. The efiect of duration of penile traction therapy in patients undergoing intralesional injection ther. ay for peyronie's disease. J Urol 2015;194:754-8. 

72. Kendiret M. Usta mit in Matern a-2b injection therapy on perile hemodynamics. impact of intralesional interferon a-2b injection therapy on penile hemodynamics, org/10.1111/J.1743-6109.2005.00110.X. men with Pevronie's disease. I Sex Med 2005:2:709 – 15 

73. Hellstrom WJG, Kendirci M, Matern R, Cockerham Y, Myers I, Silka SC, ct al. Single-blind, multicenter, placebo controlled, parallel study to assess the safety and efficacy of intralesional interferon a-2b for minimally invasive treatment for ¡Peyronie's disease. J Urol 2006;176:394-8. 

74. Polat O, Gul O, Obey I, Ozdikici M, Bayraktar Y. Peyronie's disease: intralesional treatment with interferon alpha-2A and evaluation of the results by magnetic resonance imaging. Int Urol Nephrol 1997;29:465-71. 

75. Inal T, Tokati Z, Akand M, Özdiler E, Yaman Ö. Effect of intralesional interferon-alpha 2b combined with oral vitamin E for treatment of early stage Peyronie's dis ease: a randomized and prospective study. Urology 2006;67:1038-42 

76. Gennaro R, Barletta D, Paulis G. Intralesional hyaluronic acid: an innovative tea. Gent for Reyronie's disease. Int Urol Nephrol 2015,47:1595 - 602. 

77. Lamprakopoulos A, Zorzos I, Lykourinas M. The use of betamethasone and hyal. uronidase injections in the treatment of Peyronie's disease. Scand J Urol Nephrol 2000;34:355-60. 

78. Zucchi A, Costantini E, Cai T, Cavallini G, Liguori G, Favilla V, et al. Intralesional infection of hyaluronic acid in patients affected with Peyronie's disease: preliminary results from a prospective, multicenter, pilot study. Sex Med 2016;4:83-8 

79. Muñoz-Rangel CA, Fernandez-Vivar E, Bañuelos-Gallo RA, Gonzalez-Ojeda A. Macias- Amezcua MD, Chavez-Tostado M, et al. Minimally invasive therapy using intralesional OnabotulinumtoxinA in Peyronie's disease. Urol J 2015;12:2105- 10. 

80. Alenghat FJ, Ingber DE. Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. Science's STKE: Signal Transduct Know Environ 2002:2002 

81. Ilizarov GA, Soibel'man LM. Clinical and experimental data on bloodless lengthening Of lower extremities. Eksperimental'Naia Khirurgia I Anesteziologiia 1969,14 

82. Alman BA, Greel DA, Ruby LK, Goldberg MI, Wolfe HJ. Regulation of proliferation and platelet-derived growth factor expression in palmar fibromatosis Dupuytren con-tracture) by mechanical strain. J Orthopaedic Res: Off Pabl Orthopaedic Res So 

83. 1996;14(5):722-8. Bailey AJ, Tarlton JE, Van der Stappen J, Sims TJ, Messina A. The continuous elongation technique for severe Dupuytren's disease. A biochemical mechanism. § Hand Surg (Edinburgh, Scotl) 1994;19(4):522-7. 

84. Brandes G, Messina A, Reale B. The palmar fascia after treatment by the continuous extension technique for Dupuytren's contracture. J Hand Surg (Edinburgh, Scot) 1994;19(4):528-33 

85. Levine LA, Newell M, Taylor FL. Penile traction therapy for treatment of Peyronie's disease: a single-center pilot study. J Sex Med 2008:5(6):1468-73. 

86. Gontero P, Di Marco M, Giubilei G, Bartoletti R, Pappagallo G, Tizzani A, et al. Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med 2009;6 (2):558-66. 

87. Martinez-Salamanca JI, Egui A, Moncada I, Minaya J, Ballesteros CM, Del Portillo L. et al. Acute phase Peyronie's disease management with traction device: a nonran-domized prospective controlled trial with ultrasound correlation. I Sex Med 2014:11 

88. Moncada I, Krishnappa P, Romero J, Torremade J, Fraile A, Martinez-Salamanca JI, et al. Penile traction therapy with the new device Penimaster PRO' is effective and safe in the stable phase of Peyronie's disease: a controlled multicentre study. BJU Int 

89. Ziegelmann M, Savage J, Toussi A, Alom M, Yang D, Kohler T, et al. Outcomes of a novel penile traction device (Restorex) in men with Peyronie's disease: a random-ized, single-blinded, controlled trial. J Urol 2019;202(3):599-610. 

90. Valenzuela R, Ziegelmann M, Tokar S, Hillelsohn J. The use of penile traction therapy in the management of Peyronie's disease: current evidence and future prospects. Therapeutic Adv Urol 2019;11, 1756287219838139. 

91. Levine LA, Rybak J. Traction therapy for men with shortened penis prior to penile prosthesis implantation: a pilot study. J Sex Med 2011;8(7):2112-17. 

92. Ziegelmann MJ, Viers BR, Montgomery BD, Avant RA, Savage JB, Trost IW. Clinical experience with penile traction therapy among men undergoing collagenase clostridium histolyticum for Peyronie disease. Urology 2017;104:102-9. 

93 Rybak J, Papagiannopoulos D, Levine L. A retrospective comparative study of traction therapy vs. no traction following tunica albuginea plication or partial excision and grafting for Peyronie's disease: measured lengths and patient perceptions. J Sex Med 2012;9(9):2396-403. 

94. Aber MR, Larsen S, Levine LA. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med 2012;9(1):288-95. 

95. Yafi FA, Pinsky MR, Stewart C, Sangkum P, Ates E, Trost LW, et al. The effect of duration of penile traction therapy in patients undergoing intralesional injection therapy for Peyronie's disease. I Urol 2015; 194(3):754-8. 

96. Haney NM, Kohn TP, Nichols PE, Jg Helltrom W. The effect of adjunct mechanical traction on penile length in men undergoing primary treatment for Peyronie's disease: a systematic review and meta-analysis. Urology 2018;122:110-15. 

97 Nadig PW, Ware JC, Blummof R. Noninvasive device to produce and maintain an erection-like state. Urology 1986;27(2):126-31. 

98. porst. In Porst HRY, editor. The ESSM syllabus of sexual medicine. Medix. 2012 

99 Limoge JP, Olins E, Henderson D, Donatucci CF. Minimally invasive therapies in the treatment of erectile dysfuction in anticoagulated cases: a study of satisfaction and safety. J Urol 1996;155(4):1276-9. 

100. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol 1997;15(1):78-82. 

101 Avant RA, Ziegelmann M, Nehra A, Alom M, Kohler T, Trost L. Penile traction therapy and vacuum erection devices in Peyronie's disease. Sex Med Rev 2019,7 (2):338-48. 

102. Canguven O, Talib RA, Campbell J, De Young L, El Ansari W, Al-Ansari A. Is the daily use of vacuum erection device for a month before penile prosthesis implantation beneficial? A randomized controlled trial. Andrology 2017;5(1):103-6. 

103. Randhawa K, Shukla CJ. Non-invasive treatment in the management of Peyronie's disease. Ther Adv Urol 2019. 

104. Raheem AA, Garaffa G, Raheem TA, et al. The role of vacuum pump therapy to mechanically straighten the penis in Peyronie's disease. BJU Int 2010;106(8):1178-80. 

105. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T, Weidner W. Extracorporeal shock wave therapy for Peyronie’s disease: exploratory meta-analysis of clinical trials. J Urol 2004; 171: 740-745 

106. Levine LA, Larsen SM. Surgery for Peyronie’s disease. Asian J Androl 2013, 15: 27-34. 

107. Greenfield JM, Lucas S, Levine LA. Factors affecting the loss of length associated with tunica albuginea plication for correction of penile curvature. J Urol 2006, 175: 238-41. 

108. Segal RL, Burnett AL. Surgical management for Peyronie’s disease. World J Mens Health 2013, 31: 1-11 

109. Pappas, A.M.; Hyatt, G.W. The evaluation of collagen film applied to skin defects in mice. Surg. Forum, 1960, 10, 844- 846. 

110. Mienaltowski, M.J.; Birk, D.E. Structure, physiology, and biochemistry of collagens. Adv. Exp. Med. Biol., 2014, 802, 5-29. 

111. Gordon, M.K.; Hahn, R.A. Collagens. Cell Tissue Res., 2010, 339(1), 247-257. 

112. Shoulders, M.D.; Raines, R.T. Collagen structure and sta- bility. Annu. Rev. Biochem., 2009, 78, 929-958. 

113. Gelbard M, Walsh R, Kaufman JJ. Clostridial collagenase and Peyronie disease. Urology 1980;15:536. 

114. Gelbard MK, Walsh R, Kaufman JJ. Collagenase for Peyronie’s disease experimental studies. Urol Res 1982;10:135–40. 

115. Gelbard MK, Lindner A, Kaufman JJ. The use of collagenase in the treatment of Peyronie’s disease. J Urol 1985;134:280–3. 

116. Hamilton RG, Mintz GR, Gelbard MK. Humoral immune responses in Peyronie’s disease patients receiving clostridial collagenase therapy. J Urol 1986;135:641–7. 

117. Gelbard MK, James K, Riach P, Dorey F. Collagenase vs. placebo in the treatment of Peyronie’s disease: A double-blind study. J Urol 1993;149:56–8. 

118. Gelbard M, Lipshultz LI, Tursi J, Smith T, Kaufman G, Levine LA. Phase 2b study of the clinical efficacy and safety of collagenase Clostridium histolyticum in patients with Peyronie disease. J Urol 2012;187:2268–74. 

119. Auxilium Pharmaceuticals. Peyronie’s Disease Questionnaire. [Internet]. 2012. Available at: http://www.auxilium.com/r-and- d/about-clinical-trials/peyronies-disease-questionnaire. 

120. Hellstrom WJ, Feldman R, Rosen RC, Smith T, Kaufman G, Tursi J. Bother and distress associated with Peyronie’s disease: Validation of the Peyronie’s disease questionnaire. J Urol 2013;190:627–34. 

121. Gelbard M, Goldstein I, Hellstrom WJ, McMahon CG, Smith T, Tursi J, Jones N, Kaufman GJ, Carson CC 3rd. Clinical efficacy, safety and tolerability of collagenase clostridium histolyticum for the treatment of Peyronie disease in 2 large double-blind, randomized, placebo controlled phase 3 studies. J Urol 2013;190:199–207. 

122. Dhillon S. Collagenase clostridium histolyti- cum: a review in Peyronie’s disease. Drugs 2015;75:1405-12. 

123. Somers KD, Sismour EN, Wright GL Jr, et al.Isolation and characterization of collagen in Peyronie’s disease. J Urol 1989;141:629-31. 

124. Xiapex Summury of Product Information. 2015 

125. Andrea Cocci 1, Giorgio Ivan Russo 2, Andrea Salonia 3, Gianmartin Cito 4, Federica Regis 2, Gaia Polloni 5, Gianluca Giubilei 6, Giovanni Cacciamani 7, Marco Capece 8, Marco Falcone 9, Isabella Greco 4, Massimiliano Timpano 9, Andrea Minervini 4, Mauro Gacci 4, Tommaso Cai 10, Giulio Garaffa 11, Bruno Giammusso 2, Davide Arcaniolo 8, Vincenzo Mirone 8, Nicola Mondaini 12 ;Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study; 2018 May;15(5):716-721. 

126. Nicola Mondaini, Samuele Savian, Fabio Crocerossa, Francesco Cantiello, and Rocco Damiano .Peyronie’s Disease in Teenagers: Is Collagenase Clostridium Histolyticum a Solution? JSM sexual medicine; 2022 ISSN: 2578-3718 126.2 Abdel Raheem A, Capece M, Kalejaiye O, et al. Safety and effectiveness of collage-nase clostridium histolyticum (CCH) (Xiapex®) in the treatment of Peyronie's disease using a new modified shortened protocol. BJU Int 2017. 

127. Cocci A, Russo GI, Salonia A, Cito G, Regis F, Polloni G, et al. Predictive factors of patients' and their partners' sexual function improvement after collagenase clostridium histolyticum iniection for peronie's disease: results from a multicenter single-arm study. J Sex Med 2018;15 (5):716-21. 

128. Fernández-Pascual E, González-García E], Angulo J, Cerezo E, Quintana IM, Turo J, et al. Optimizing collagenase Clostridium histolyticum therapy for Peyronie's disease using a novel approach with percutaneous needle tunnelling. BJU Int 2019;29. 

129. Rosen RC, et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997;49:822. 

130. Chen JY, Hockenberry MS, Lipshultz LI. Objective Assessment of Peyronie's disease. Sex Med Rev 2018;6(3):438-45. 

131 Andrea Cocci , Fabrizio Di Maida , Giorgio Ivan Russo , Paolo Capogrosso, Francesco Lotti, Michele Rizzo , Marina Di Mauro Andrea Salonia ,Gianmartin Cito 1, Marco Falcone 7, Andrea Romano 1, Gaia Polloni 8, Juan Ignacio Martinez-Salamanca 9, Esaù Fernández-Pascual 9, Andrea Minervini 1, Nicola Mondaini 10Correction to: Efficacy of Collagenase Clostridium histolyticum (Xiapex®) in Patients with the Acute Phase of Peyronie's Disease :2021 May;41(5):497. 

132 M Capece 1, A Cocci 2, G Russo 3, G Cito 2, G Giubilei 4, G Cacciamani 5, G Garaffa 6, M Falcone 7, M Timpano 7, G Tasso 2, F Sessa 2, R Campi 2, F Di Maida 2, T Cai 8, G Morelli 9, B Giammusso 3, P Verze 1, A Palmieri 1, D Ralph 6, V Mirone 1, N Mondaini 10;Collagenase clostridium histolyticum for the treatment of Peyronie's disease: a prospective Italian multicentric study. ;2018 Jul;6(4):564-567. 

133 Andrea Cocci 1, Fabrizio Di Maida 2, Giorgio Ivan Russo 3, Marina Di Mauro 3, Gianmartin Cito 2, Marco Falcone 4, Andrea Minervini 2, Giovanni Cacciamani 5, Riccardo Campi 2, Andrea Mari 2, Francesco Sessa 2, Nicola Mondaini 6 ; Epub 2019 May 29.;How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium HistolyticumTherapy? 2020 Jan;38(1):78-84. 

134. Andrea Cocci 1, Giorgio Ivan Russo 2, Andrea Salonia 3, Gianmartin Cito 4, Federica Regis 2, Gaia Polloni 5, Gianluca Giubilei 6, Giovanni Cacciamani 7, Marco Capece 8, Marco Falcone 9, Isabella Greco 4, Massimiliano Timpano 9, Andrea Minervini 4, Mauro Gacci 4, Tommaso Cai 10, Giulio Garaffa 11, Bruno Giammusso 2, Davide Arcaniolo 8, Vincenzo Mirone 8, Nicola Mondaini 12 ;Predictive Factors of Patients' and Their Partners' Sexual Function Improvement After Collagenase Clostridium Histolyticum Injection for Peyronie's Disease: Results From a Multi-Center Single-Arm Study ;2018 May;15(5):716-721. 

135. Fala L. Xiaflex (Collagenase ClostridiumHistolytioum), First Drug Approved by the FDA for Peyronie's Disease. American Health & Drug Benefits. 2014 March; 7: p. Special Feature. 

136. European Medicines Agency. Xiapex (collagenase Clostridium histolyticum): summary of product characteristics. 

137. Cocci A, Russo GI, Salamanca JIM, Ralph D, Palmieri A, Mondaini N. The End of an Era: Withdrawal of Xiapex (Clostridium histolyticum Collagenase) from the European Market. Eur Urol. 2020 May;77(5):660-661. 

138. Cocci A, Russo GI, Martinez-Salamanca JI, Ralph D, Djinovic R, Şerefoğlu EC, Mondaini N. Is there a line between ethics and market competition? Lights and shades of the withdrawal of collagenase treatment for Peyronie's disease. Int J Impot Res. 2022 Dec;34(8):733-734.